Comparative Pharmacology
Head-to-head clinical analysis: Q PAM versus TAMSULOSIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: Q PAM versus TAMSULOSIN HYDROCHLORIDE.
Q-PAM vs TAMSULOSIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Q-PAM is a quaternary ammonium neuromuscular blocking agent that competitively blocks acetylcholine at nicotinic receptors at the neuromuscular junction, causing depolarizing neuromuscular blockade.
Selective antagonist of alpha-1A and alpha-1D adrenergic receptors in the prostate, bladder neck, and prostatic urethra, causing smooth muscle relaxation and improved urine flow.
100 mg orally twice daily
0.4 mg orally once daily, approximately 30 minutes after the same meal each day. For patients who fail to respond to 0.4 mg after 2-4 weeks, dose may be increased to 0.8 mg once daily.
None Documented
None Documented
Terminal half-life: 8-12 hours (mean 10 h) in healthy adults. Prolonged in renal impairment (up to 24 h in CrCl <30 mL/min); no dose adjustment needed in mild-moderate hepatic impairment.
9-13 hours in healthy subjects, but can increase to 14-16 hours in elderly patients. This supports once-daily dosing, though steady-state is reached by day 5.
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; total clearance ~12 L/h.
Primarily hepatic metabolism (CYP3A4 and CYP2D6) followed by renal excretion. Approximately 75-90% of a dose is excreted in urine as inactive metabolites, with <10% as unchanged drug. Fecal excretion accounts for 10-15%.
Category C
Category A/B
Alpha-1 Blocker
Alpha-1 Blocker